United States - English - NLM (National Library of Medicine)

mylan institutional llc - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 38 mg in 1 ml - gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine injection is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine injection is indicated for patients previously treated with fluorouracil. gemcitabine injection is contraindicated in patients with

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine 200 mg in 5 ml - gemcitabine for injection, usp in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine for injection, usp in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine for injection, usp in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine for injection, usp is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine for injection, usp is indicated for patients previously treated with fluorouracil. gemcitabine f

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fresenius kabi ltd - gemcitabine hydrochloride - solution for infusion - 38mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fresenius kabi ltd - gemcitabine hydrochloride - solution for infusion - 38mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fresenius kabi ltd - gemcitabine hydrochloride - solution for infusion - 38mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml;   - concentrate for injection - 10 mg/ml - active: gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml   excipient: sodium acetate trihydrate sodium hydroxide water for injection - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine;  ;   - powder for injection - 200 mg - active: gemcitabine hydrochloride 228mg equivalent to 200 mg gemcitabine     excipient: mannitol nitrogen sodium acetate as sodium acetate trihydrate sodium hydroxide - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Singapore - English - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - gemcitabine hydrochloride 43.2668mg/ml eqv to gemcitabine - infusion, solution concentrate - gemcitabine hydrochloride 43.2668mg/ml eqv to gemcitabine 38mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - gemcitabine hydrochloride, quantity: 228 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed >six months following platinum based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 569.5 mg (equivalent: gemcitabine, qty 500 mg) - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; sodium acetate trihydrate - gemcitabine sandoz is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (nsclc). - locally advanced or metastatic adenocarcinoma of the pancreas . - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.